Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label BMN 045 exon 45 skipping study in Duchenne muscular dystrophy
NL-OMON43779Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosoritide in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Change from baseline in 6-minute walk distance. Started Aug 2013; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON43779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43779.